Priming regiments based on idarubicin or aclacinomycin or pirarubicin in the treatment of refractory/relapsed acute lymphoblastic leukemia: a clinical control study
MIAO Yu-qing
ZHU Jian-feng
ZHANG Yan-ming
XU Hao
WU Zheng-dong
SUN Ying-xin
ZHU Yu
ZHU Hua-yuan
HE Guang-sheng
LI Jian-yong
Keywords：acute lymphoblastic leukemiapriming regimensrefractoryrelapsedidarubicinaclacinomycinpirarubicin
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 845-847 )